Peptides and Menopause: What Has Evidence

Why Stage Matters More Than Peptide

Search "peptides for menopause" and you get ranked lists. Five peptides, seven peptides, the top ten. The lists share a flaw: they treat menopause as one condition with one set of symptoms, and they treat a 46-year-old with wild cycles and a 63-year-old ten years past her last period as the same patient. A prescriber does not think that way, and the difference is not academic. The woman in perimenopause is dealing with a hormone level that swings week to week. The woman in late postmenopause is dealing with a hormone level that is stable and low, plus a decade of downstream consequences in muscle, bone, skin, and sleep that have already accumulated.

This page is built around that distinction. It walks the three stages defined by the Stages of Reproductive Aging Workshop (the STRAW+10 criteria that clinicians use), describes what physiologically changes in each, and only then asks which peptide categories touch which change. The evidence for each category is graded plainly, because most of it is thinner than the marketing suggests and some of it belongs to FDA-approved drugs rather than to the compounded peptides anyone is actually buying.

Two things this page is not. It is not a symptom-by-symptom guide to perimenopause; that already exists at peptides for perimenopause symptoms Read nextPeptides for Perimenopause Symptoms: Sleep, Joints, and LibidoPerimenopause shows up as broken sleep, new joint aches, and a drop in desire, often all at once. Which peptides target each piece of the cluster, and where they fit alongside hormone therapy.Read article . And it is not a deep dive on GLP-1s and midlife weight, which lives at semaglutide and menopause Read nextSemaglutide and Menopause: Does It Still Work?Somewhere in the mid-40s, the strategies that always worked stop working. Same food, same walks, new midsection. Then comes the question nobody answers well: does a GLP-1 even work after menopause, and does hormone therapy change the math? The cohort data exists. This page walks through it, plus the muscle problem that matters more for this reader than for almost anyone else.Read article . If you want a general ranking for women over 40, that page is here Read nextBest Peptides for Women Over 40: What Actually WorksWhich peptides target the specific biological changes women face after 40: GH decline, body composition, skin quality, sleep, and recovery.Read article . This one is the framework that sits above all three.

What Changes, Stage by Stage

Menopause is not a single event. STRAW+10 divides reproductive aging into stages, and the three that matter for this conversation are the transition itself, the final menstrual period, and the years after. Each carries a different biological picture.

Perimenopause: volatility, not decline

The defining feature of perimenopause is not low estrogen. It is unpredictable estrogen. Cycles lengthen and shorten, ovulation becomes intermittent, progesterone falls first because anovulatory cycles produce none, and estradiol can spike higher than it did at 30 before crashing the following week. Symptoms track the volatility: sleep breaks up, mood swings, hot flashes start, and joint aches appear seemingly out of nowhere. Body composition begins to shift, but the large changes are still ahead.

This matters for peptides because most peptides act slowly and steadily over weeks. A growth hormone secretagogue taken nightly does not do anything about a hormone that is swinging on a seven-day timescale. Sleep peptides and libido peptides are at least aimed at the right symptoms, but they are aimed at symptoms driven by a moving target.

Menopause: the reset

Menopause is defined retrospectively, twelve months after the last period. The average age in the United States is 51. At this point estradiol has settled at a low, stable level and the body begins adapting to it. The SWAN cohort, which followed women through the transition with repeated body-composition scans, found that fat mass rises and lean mass falls during the transition and then those trajectories flatten a few years after the final period (Greendale et al., JCI Insight, 2019). Vasomotor symptoms are usually at their worst in the year or two on either side of this point.

Two other systems shift here in ways that are directly relevant to peptides. Growth hormone secretion, which had already been declining through adulthood, loses the amplifying effect estrogen has on it. Reviews of the GH/IGF-1 axis in aging describe the drop in GH pulse amplitude as one of the more consistent endocrine changes of midlife (Junnila et al., Nature Reviews Endocrinology, 2013). And skin collagen, which is estrogen-dependent, begins to fall. Brincat and colleagues measured a drop in skin collagen content and thickness in the early postmenopausal years and found it tracked years since menopause more closely than chronological age (Obstetrics and Gynecology, 1987).

Postmenopause: the accumulated result

Postmenopause is where the consequences compound. Sleep architecture changes are measurable: a longitudinal polysomnography analysis from the SWAN sleep study found the transition was associated with changes in sleep continuity and slow-wave sleep that persisted after the final period (Matthews et al., Sleep, 2021). Muscle loss becomes the dominant body-composition problem rather than fat gain alone. Bone density, which estrogen protected, declines. Vaginal and urinary tissue changes appear. Desire often falls, though the reasons are mixed: hormonal, relational, and a function of sleep and energy.

For a prescriber, the postmenopausal patient is where the GH secretagogue question becomes most reasonable, because GH decline is now stable and measurable through IGF-1, and where the risk conversation matters most, because this is also the age where cancer screening, cardiovascular risk, and glucose regulation carry the most weight.

Harlow SD, Gass M, Hall JE, et al. "Executive summary of the Stages of Reproductive Aging Workshop + 10." J Clin Endocrinol Metab, 2012. PMID 22344196. View study

Greendale GA, Sternfeld B, Huang M, et al. "Changes in body composition and weight during the menopause transition." JCI Insight, 2019. PMID 30843880. View study

Matthews KA, Lee L, Kravitz HM, et al. "Influence of the menopausal transition on polysomnographic sleep characteristics: a longitudinal analysis." Sleep, 2021. PMID 34081126. View study

Peptide Categories, Mapped to the Change

Here is the map. Read the third column carefully, because it is the one the ranked lists leave out.

Notice what the last row says. The symptoms most people mean when they say "menopause," the vasomotor and genitourinary ones, are not addressed by any peptide category. Anyone who tells you otherwise is selling something. The peptide conversation is legitimately about the second-order changes: body composition, sleep depth, skin, and desire.

The Evidence, Graded Honestly

GH secretagogues: real physiology, no menopause trial

Sermorelin Read nextSermorelin 2026: The Original Growth Hormone PeptideEvery growth hormone peptide used today traces its lineage back to this molecule. Sermorelin was once FDA-approved, then abandoned for commercial reasons. Now it's having a second act as the safest entry point into growth hormone optimization.Read article is a synthetic fragment of growth hormone-releasing hormone. CJC-1295 is a longer-acting GHRH analog and ipamorelin is a ghrelin-receptor agonist, and together they raise GH through two pathways. Tesamorelin Explore PeRxTesamorelinMetabolic Optimization PeptideView peptide is a GHRH analog with an FDA approval, though for HIV-associated abdominal fat, not for menopause. The common thread is that these compounds ask the pituitary to release more of the patient's own GH rather than injecting GH directly, which is the reason prescribers prefer them: the body's feedback loops stay intact.

The evidence that they raise GH and IGF-1 in adults is solid. A 2018 review in Sexual Medicine Reviews summarized the secretagogue literature and concluded that these agents reliably increase IGF-1 with a favorable short-term safety profile, while noting the absence of long-term outcome data (Sigalos and Pastuszak, 2018). The most relevant controlled trial for an older population is Baker and colleagues' 20-week study of tesamorelin in 152 healthy older adults and adults with mild cognitive impairment, which found improvements in executive function alongside the expected IGF-1 rise (Archives of Neurology, 2012). Roughly half the participants were women, but the study was not designed around menopause and did not stratify by it.

So the honest grade is this: there is moderate evidence that GH secretagogues do what they are supposed to do hormonally, and there is no trial showing that doing it improves a menopausal outcome. Reports of better sleep depth and slow recomposition over months are consistent with GH physiology and are what patients commonly describe, but they are not trial results. This is the category most reasonable for the postmenopausal patient with a low IGF-1 and a lean-mass complaint, and least reasonable as a first move in perimenopause. Dosing considerations for the older end of this range are covered in peptides after 60 Read nextPeptides After 60: Dosing Adjustments and What the Research ShowsPeptide therapy after 60 is not the same protocol at a lower weight. Conservative GH secretagogue starts, cancer and diabetes screening, polypharmacy review, and age-aware cycling.Read article .

Sigalos JT, Pastuszak AW. "The Safety and Efficacy of Growth Hormone Secretagogues." Sex Med Rev, 2018. PMID 28400207. View study

Baker LD, Barsness SM, Borson S, et al. "Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial." Arch Neurol, 2012. PMID 22869065. View study

GHK-Cu: strong biology, mostly topical data

GHK-Cu Explore PeRxGHK-CuThe Skin Rejuvenation PeptideView peptide is a copper-binding tripeptide that declines in plasma with age. Pickart's 2015 review catalogued its effects on collagen synthesis, wound remodeling, and gene expression in skin fibroblasts, and the topical cosmetic literature includes small human studies showing improvements in skin thickness and wrinkle depth (Biomed Research International, 2015). The biological rationale for a postmenopausal woman losing collagen is coherent. What is missing is injectable human data, and what exists for the topical route was not done in a menopausal cohort. Grade it low to moderate for skin, and note that GHK-Cu does nothing about the estrogen deficiency that is causing the collagen loss in the first place. The full picture is in the GHK-Cu guide Read nextGHK-Cu Copper Peptide 2026: Skin, Hair & Tissue RepairHow GHK-Cu rebuilds collagen, influences thousands of genes, and helps skin and hair, plus the research, dosage, side effects, and how the injectable differs from topical copper-peptide skincare.Read article .

Pickart L, Vasquez-Soltero JM, Margolina A. "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration." Biomed Res Int, 2015. PMID 26236730. View study

DSIP and Pinealon: old data, small studies

Delta sleep-inducing peptide was isolated in the 1970s and studied in humans through the 1980s and 1990s in small trials, some showing improved sleep measures and others showing nothing. The literature never matured into a modern controlled trial, and there is no study in menopausal women. Pinealon is a short synthetic peptide from the Russian bioregulator tradition with even less published human data. Both are prescribed for sleep on the strength of plausibility and patient report, not trial evidence. For a perimenopausal woman whose night waking is driven by hot flashes, neither addresses the cause. Grade: low.

PT-141: the approved version has a boundary

This is the category where the labeling nuance matters most. Bremelanotide was approved by the FDA on June 21, 2019 as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women. The pivotal trials that supported approval enrolled premenopausal women, and in those trials about 25 percent of treated patients had a meaningful increase in desire score versus about 17 percent on placebo (Kingsberg et al., Obstetrics and Gynecology, 2019). The approval is specific to premenopausal women; postmenopausal women were not the approved population.

Compounded PT-141 Explore PeRxPT-141On-Demand Intimacy EnhancementView peptide is the same molecule prepared by a 503A pharmacy per prescription, and it has not been through FDA review. Prescribers do consider it for postmenopausal patients, and the mechanism, melanocortin receptor activation in the brain rather than any hormonal pathway, does not depend on estrogen. But that is reasoning from mechanism, not from a postmenopausal trial. Grade: high for the approved drug in its approved population, limited beyond that. The practical side, including the transient blood pressure rise and the nausea that is the most common side effect, is covered in PT-141 for women Read nextPT-141 for Women: Low Libido, Vyleesi, and What to ExpectThe only FDA-approved medication that targets female sexual desire in the brain. Who it helps, the premenopausal HSDD approval, and how it compares to Addyi.Read article .

Kingsberg SA, Clayton AH, Portman D, et al. "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials." Obstet Gynecol, 2019. PMID 31599840. View study

GLP-1s: strong data, but read the label carefully

Semaglutide and tirzepatide are the only category on this page with large, modern, FDA-reviewed evidence, and it belongs to the approved products: Wegovy and Ozempic for semaglutide, Zepbound and Mounjaro for tirzepatide. PeRx prescribes compounded semaglutide with B12 and compounded tirzepatide with B12, prepared per prescription by a 503A pharmacy. Those compounded preparations have not been through FDA review, and the published trial results describe the approved drugs, not the compounded ones. That distinction is not fine print. It is the whole legal structure, and gray-market versus compounded GLP-1s Read nextGray-Market GLP-1s vs Compounded: What Testing MissesThis page is for the person doing spreadsheet math on a $44 internet vial versus a legitimate prescription. No moralizing and no scare quotes. What the three tiers of GLP-1 supply legally are, what a certificate of analysis actually proves, what it cannot, and what each route really costs per month.Read article explains it in detail.

The midlife-specific data is small but interesting. A Mayo Clinic retrospective study of 106 postmenopausal women treated with semaglutide found that the sixteen who were also on menopausal hormone therapy lost more weight at every timepoint than the ninety who were not (Hurtado et al., Menopause, 2024). It is a retrospective cohort with a small hormone-therapy arm, and it studied the approved drug, so it is a hypothesis rather than a rule. It is also the single most useful data point for the reader of this page, because it suggests HRT and a GLP-1 are not in competition. Muscle preservation is the specific concern in this stage, since lean mass is already falling, and that is worked through at semaglutide and menopause Read nextSemaglutide and Menopause: Does It Still Work?Somewhere in the mid-40s, the strategies that always worked stop working. Same food, same walks, new midsection. Then comes the question nobody answers well: does a GLP-1 even work after menopause, and does hormone therapy change the math? The cohort data exists. This page walks through it, plus the muscle problem that matters more for this reader than for almost anyone else.Read article .

Hurtado MD, Tama E, Fansa S, et al. "Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use." Menopause, 2024. PMID 38446869. View study

What Peptides Are Not

Peptides are not hormone replacement. None of the compounds on this page raise estradiol, progesterone, or testosterone. A GH secretagogue raises growth hormone, which is a hormone, but it is not the hormone that fell at menopause, and raising it does nothing for hot flashes, vaginal atrophy, or bone density in the way estrogen does. Anyone using peptides as a reason to avoid a conversation about HRT has the risk calculus backwards.

The 2022 position statement of The North American Menopause Society, which renamed itself The Menopause Society in 2023, is unambiguous: hormone therapy remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause, and for most healthy women under 60 or within ten years of menopause onset, the benefits outweigh the risks (Menopause, 2022). That statement does not mention peptides at all, which tells you where they sit in the evidence hierarchy. Non-hormonal approved options exist for women who cannot or prefer not to use estrogen, and a peptide is not one of them.

Peptides are also not FDA-approved for any menopausal use. The one peptide on this page with an approval, bremelanotide, is approved for premenopausal HSDD. The compounded GLP-1s ride on the approvals of other products. Everything else is prescribed off-label under a physician's judgment, and the FDA's position on compounding these peptides has been in motion through 2026: several were removed from the Category 2 bulk substances list in April 2026, and a July 2026 advisory committee vote recommending a path forward for some of them remains a non-binding recommendation. The current state is summarized at will the FDA ban peptides Read nextWill the FDA Ban Peptides in 2026? What the Data SaysSearch "FDA peptide ban" and you get panic in one direction and "they're legal again" in the other. Both are wrong. The precise, physician-reviewed answer to whether the FDA is banning peptides in 2026.Read article .

"The 2022 hormone therapy position statement of The North American Menopause Society" Advisory Panel. Menopause, 2022. PMID 35797481. View study

Peptides Alongside HRT

Most women reading this page are either on HRT or considering it, so the practical question is whether the two coexist. There is no documented pharmacologic interaction between estradiol, progesterone, or testosterone therapy and any peptide in the categories above. That is partly reassuring and partly a reflection of how little the combination has been studied. What follows is how a careful prescriber handles it.

Disclose every hormone and its route, because the route changes the number a prescriber reads. In a randomized crossover study of 18 postmenopausal women, oral estrogen lowered IGF-1 while transdermal estrogen did not, a difference driven by first-pass liver metabolism (O'Sullivan et al., Journal of Clinical Investigation, 1998). Mean IGF-1 was 77 micrograms per liter on oral estrogen versus 97 on transdermal in the same women. That gap is large enough to change whether an IGF-1 result looks low, which matters when IGF-1 is the marker being used to weigh a GH secretagogue. A prescriber who does not know which route you use cannot interpret the result correctly.

O'Sullivan AJ, Crampton LJ, Freund J, Ho KK. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. Journal of Clinical Investigation. 1998;102(5):1035-1040. View study

Disclose testosterone if you use it, and its dose. Some women on menopausal regimens receive low-dose testosterone for libido, which changes the reasoning about PT-141 and about GH secretagogues. Disclose thyroid medication, since GH and thyroid axes interact and hypothyroidism blunts the IGF-1 response. And disclose any history of estrogen-sensitive cancer, since that shifts the whole conversation regardless of which peptide is on the table.

On the GLP-1 side, the Hurtado cohort is the reason not to assume that HRT and a GLP-1 conflict. The data suggests the opposite, though the cohort was small and studied the approved drug. Sequence matters in practice: a woman starting both at once cannot tell which one is producing which effect, so many prescribers prefer to settle HRT first and add a peptide or GLP-1 afterward.

The Lab Work Conversation

A menopausal patient asking about peptides is usually already having labs drawn for other reasons, which makes this the easiest stage of life to arrive at a peptide consult prepared. The general list is covered at lab work before starting peptides Read nextLab Work Before Starting PeptidesThe honest answer to "what bloodwork do I need before peptides?" is: it depends on the peptide, and for many of them the answer is none. Some sites will tell you to buy a full baseline panel before anything, because they sell the panel. Here is the real picture, which peptides typically need no labs, where a provider may want to check IGF-1 and a metabolic panel, and why the decision belongs to the provider reviewing your history rather than to a checklist.Read article . The additions specific to this stage:

IGF-1 is the marker that makes a GH secretagogue conversation concrete. A postmenopausal woman with an IGF-1 in the lower part of the age-adjusted range has a measurable rationale; one with a mid-range IGF-1 has less. Ask for the age-referenced range, not the generic adult range, and note whether you take oral estrogen, which lowers it.

Fasting glucose or A1c matters twice over. Insulin resistance rises after menopause, GH secretagogues can nudge glucose upward, and a GLP-1 will move it the other way. A prescriber weighing which category fits wants this number first.

Lipids and blood pressure are standard midlife screening and also bear on PT-141, which causes a transient blood pressure rise after each dose. TSH rules out the thyroid explanation for fatigue and poor sleep before a peptide is blamed or credited. And FSH and estradiol are not needed to diagnose menopause after 45, but if you are on HRT the estradiol level helps the prescriber understand your baseline.

Bring the results, not the peptide name. A patient who arrives with "my IGF-1 is 95 and my A1c is 5.9 and my main complaint is muscle loss" has given the prescriber what they need to match a category to a stage. A patient who arrives with "I want sermorelin Explore PeRxSermorelinThe Growth Hormone OptimizerView peptide " has skipped the step that makes the choice defensible.

Questions to Bring to Your Prescriber

These are the questions a well-prepared patient asks in a peptide consult during or after menopause. If the provider cannot answer them plainly, that is information too.

1. Which stage am I in by STRAW+10 criteria, and does that change your recommendation? A prescriber who does not distinguish perimenopause from postmenopause is working from a list.

2. Which specific change is this peptide meant to address, and what is the evidence for that use in women my age? "It helps with menopause" is not an answer. "It raises GH pulses, which we can track with IGF-1, and the menopause-specific trial data does not exist" is.

3. Is there an FDA-approved option for this symptom that I should try first? For hot flashes, low desire in premenopausal women, and weight, the answer is yes, and a good prescriber will say so.

4. How does this sit with my HRT, my route of estrogen, and my testosterone if I use it? See the section above; the prescriber should ask you this before you ask them.

5. What will we measure, and when would we stop? For a GH secretagogue, IGF-1 and glucose at baseline and again after a cycle. For a GLP-1, weight and a body-composition estimate. For a sleep or skin peptide, an honest admission that there is no lab marker and the trial is you.

6. What is the pharmacy, and is this a 503A compounded product prepared for me by prescription? The only right answer for any peptide is a licensed compounding pharmacy on an individual prescription. Anything labeled for research is a different product, and where to buy peptides legally explains why.

7. What does this cost per cycle, and is it a subscription? At PeRx, peptides are per-prescription with no auto-renewal, and the two compounded GLP-1s are the only subscriptions, one vial per 28 days with a provider review each cycle. Ask any provider the same question.

If after all of that a peptide still makes sense, the process at PeRx is an online intake reviewed by a licensed provider, and if appropriate, your PeRx provider will prescribe a protocol filled by a US 503A pharmacy. Vials ship fully reconstituted and ready to use, overnight in cold packaging. The catalog is at /peptides, and what providers review before prescribing Read nextWhat Providers Review Before Prescribing PeptidesWhen your intake reaches a licensed provider, it is not a rubber stamp. Here is the checklist they run from the other side of the screen: the conditions that change whether a peptide is safe, the medications that get cross-checked, and what gets escalated or declined.Read article describes what the intake actually screens for.

Common Questions